Biodesix Narrows Q3 Loss on Strong 20% Revenue Growth

TL;DR

**BDSX is burning cash despite revenue growth; watch for future capital raises as losses persist.**

AI Summary

BIODESIX INC (BDSX) reported a net loss of $8.716 million for the three months ended September 30, 2025, an improvement from a net loss of $10.258 million in the same period of 2024. Revenues increased significantly to $21.768 million for Q3 2025, up from $18.151 million in Q3 2024, representing a 19.9% year-over-year growth. For the nine months ended September 30, 2025, the company's net loss was $31.285 million, an improvement from $34.680 million in the prior year, while revenues grew to $59.744 million from $50.894 million, a 17.4% increase. Operating expenses rose to $28.819 million in Q3 2025 from $26.742 million in Q3 2024, primarily driven by increased sales, marketing, general and administrative expenses, which reached $21.714 million. The company's cash and cash equivalents decreased to $16.604 million as of September 30, 2025, from $26.245 million at December 31, 2024, reflecting significant cash usage in operating activities of $24.049 million over the nine-month period. A 1-for-20 reverse stock split was effective September 15, 2025, impacting share and per-share data.

Why It Matters

Biodesix's continued revenue growth, particularly in its diagnostic tests for lung cancer, signals increasing market acceptance and potential for long-term value creation for investors. However, the persistent net losses and significant cash burn, with cash and cash equivalents dropping by nearly $10 million in nine months, raise concerns about liquidity and the need for future capital raises. For employees, sustained revenue growth could mean job security and expansion, while customers benefit from improved diagnostic solutions. In a competitive landscape, Biodesix's multi-omic approach and established tests like Nodify Lung are crucial differentiators, but the company must accelerate its path to profitability to maintain its market position and attract further investment.

Risk Assessment

Risk Level: high — The company reported a net loss of $31.285 million for the nine months ended September 30, 2025, and a negative total stockholders' equity of $(1,722) thousand, indicating a precarious financial position. Cash and cash equivalents decreased by $9.640 million during the nine-month period, with $24.049 million used in operating activities, highlighting significant liquidity challenges and a reliance on financing activities, which provided $14.708 million.

Analyst Insight

Investors should exercise caution and closely monitor Biodesix's cash burn rate and future financing activities. While revenue growth is positive, the company's negative equity and substantial operating losses suggest a high risk profile. Consider waiting for clear signs of reduced cash usage or a definitive path to profitability before making significant investments.

Financial Highlights

debt To Equity

N/A

revenue

$59.744M

operating Margin

N/A

total Assets

N/A

total Debt

$47.111M

net Income

-$31.285M

eps

-$1.722

gross Margin

N/A

cash Position

$16.604M

revenue Growth

+17.4%

Key Numbers

• $21.768M — Q3 2025 Revenue (Increased 19.9% from Q3 2024)
• $8.716M — Q3 2025 Net Loss (Improved from $10.258M loss in Q3 2024)
• $59.744M — YTD 2025 Revenue (Increased 17.4% from YTD 2024)
• $31.285M — YTD 2025 Net Loss (Improved from $34.680M loss in YTD 2024)
• $16.604M — Cash & Cash Equivalents (As of September 30, 2025, down from $26.245M at Dec 31, 2024)
• $24.049M — Cash Used in Operations (For the nine months ended September 30, 2025)
• $(1.16) — Q3 2025 Net Loss Per Share (Improved from $(1.40) in Q3 2024)
• 1-for-20 — Reverse Stock Split (Effective September 15, 2025)
• $47.111M — Long-term notes payable (As of September 30, 2025, up from $36.408M at Dec 31, 2024)
• $(1.722)M — Total Stockholders' (Deficit) Equity (As of September 30, 2025, down from $20.876M at Dec 31, 2024)

Key Players & Entities

• BIODESIX INC (company) — Registrant in 10-Q filing
• Nasdaq Stock Market LLC (regulator) — Exchange where common stock is registered
• SEC (regulator) — Securities and Exchange Commission
• Nodify CDT (company) — Blood-based lung diagnostic test
• Nodify XL2 (company) — Blood-based lung diagnostic test
• $21.768 million (dollar_amount) — Total revenues for Q3 2025
• $18.151 million (dollar_amount) — Total revenues for Q3 2024
• $8.716 million (dollar_amount) — Net loss for Q3 2025
• $10.258 million (dollar_amount) — Net loss for Q3 2024
• $16.604 million (dollar_amount) — Cash and cash equivalents as of September 30, 2025

FAQ

Risk Factors

• Inability to Achieve or Sustain Profitability [high — financial]: The company faces substantial risks regarding its ability to achieve or sustain profitability. This is evidenced by the continued net losses reported, such as the $8.716 million loss in Q3 2025 and a year-to-date loss of $31.285 million, despite revenue growth.
• Market Acceptance of Diagnostic Tests [high — market]: A key risk is the company's ability to attain significant market acceptance for its diagnostic tests among payers, providers, clinics, patients, and biopharmaceutical companies. Failure to achieve this acceptance directly impacts revenue generation and growth potential.
• Managing Growth and Operational Disruption [medium — operational]: Difficulties in managing the company's growth could disrupt operations. This risk is amplified by the reported increase in operating expenses to $28.819 million in Q3 2025, driven by sales, marketing, and administrative costs.
• Sales and Marketing Personnel Retention [medium — operational]: Failure to retain sales and marketing personnel, and to increase sales and marketing capabilities, poses a risk to revenue growth and the development of broad awareness for diagnostic tests. This is a critical component for driving top-line performance.
• Biopharmaceutical Company Relationships [medium — market]: The company's ability to maintain current relationships, or enter into new ones, with biopharmaceutical companies is crucial. These partnerships are likely key drivers for the adoption and commercialization of their diagnostic tests.
• Fluctuation in Operating Results [medium — financial]: Significant fluctuations in operating results are a risk, potentially causing performance to fall below expectations or any provided guidance. This volatility can impact investor confidence and financial planning.
• Product Performance and Reliability [medium — operational]: The performance and reliability of the company's products are essential for maintaining and growing the business. Any issues in this area could lead to reputational damage and loss of market share.
• Reliance on Third-Party Suppliers [low — operational]: The company's reliance on third-party suppliers, including courier services, presents an operational risk. Disruptions from these suppliers could impact the delivery and effectiveness of their diagnostic services.

Industry Context

BIODESIX operates in the diagnostics and biopharmaceutical services sector, focusing on diagnostic tests. The competitive landscape likely involves other companies developing similar technologies and seeking partnerships with biopharmaceutical firms for drug development and companion diagnostics. Key industry trends include the increasing demand for personalized medicine, advancements in molecular diagnostics, and the growing importance of strategic collaborations between diagnostic companies and drug developers.

Regulatory Implications

As a diagnostics company, BIODESIX is subject to regulatory oversight from bodies like the FDA, particularly concerning the development, validation, and marketing of its tests. Compliance with healthcare regulations, data privacy laws (e.g., HIPAA), and quality management systems is critical. Failure to adhere to these regulations could result in fines, product recalls, or restrictions on operations.

What Investors Should Do

1. Monitor cash burn rate and runway.
2. Evaluate the sustainability of revenue growth.
3. Assess the impact of the reverse stock split.
4. Analyze the increase in long-term debt.

Key Dates

• 2025-09-30: End of Third Quarter 2025 — Reporting period for the Q3 and YTD financial results, showing revenue growth and reduced net loss, but also a decrease in cash reserves.
• 2025-09-15: Reverse Stock Split Effective — A 1-for-20 reverse stock split was enacted, impacting share counts and per-share data, which is crucial for understanding EPS trends.
• 2025-03-03: Form 10-K for year ended Dec 31, 2024 filed — This filing contains important risk factors and historical context that are referenced in the current 10-Q.

Glossary

Reverse Stock Split

A corporate action where a company reduces the number of its outstanding shares by consolidating them. For example, a 1-for-20 split means every 20 old shares become 1 new share. (Effective September 15, 2025, this action impacts share count and per-share metrics like EPS, making historical comparisons require adjustment.)

Net Loss

The total expenses incurred by a company exceed its total revenues over a specific period. (BIODESIX reported net losses of $8.716 million for Q3 2025 and $31.285 million year-to-date, indicating the company is not yet profitable.)

Cash and Cash Equivalents

Highly liquid short-term investments that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value. (The company's cash position decreased to $16.604 million as of September 30, 2025, highlighting significant cash burn from operations.)

Operating Expenses

Costs incurred by a company in its normal course of business, excluding cost of goods sold. This includes selling, general, and administrative (SG&A) expenses. (Operating expenses increased to $28.819 million in Q3 2025, primarily driven by higher sales, marketing, and administrative costs.)

Stockholders' (Deficit) Equity

The residual interest in the assets of an entity after deducting all its liabilities. A deficit means liabilities exceed assets. (The company has a negative stockholders' equity of $(1.722) million as of September 30, 2025, indicating a deficit.)

Long-term notes payable

Debt obligations that are due more than one year from the balance sheet date. (This debt increased to $47.111 million as of September 30, 2025, representing a significant portion of the company's liabilities.)

Year-Over-Year Comparison

Compared to the previous year, BIODESIX INC has demonstrated revenue growth, with Q3 2025 revenue up 19.9% year-over-year to $21.768 million and year-to-date revenue up 17.4% to $59.744 million. The net loss has also narrowed, improving from $10.258 million in Q3 2024 to $8.716 million in Q3 2025, and from $34.680 million to $31.285 million year-to-date. However, operating expenses have risen, and the company's cash position has significantly decreased from $26.245 million at the end of 2024 to $16.604 million as of September 30, 2025, indicating increased cash burn. New risk factors related to managing growth and maintaining biopharmaceutical relationships are highlighted.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share BDSX The Nasdaq Stock Mar

Filing Documents

• bdsx-20250930.htm (10-Q) — 2609KB
• bdsx-ex10_1.htm (EX-10.1) — 26KB
• bdsx-ex31_1.htm (EX-31.1) — 16KB
• bdsx-ex31_2.htm (EX-31.2) — 16KB
• bdsx-ex32_1.htm (EX-32.1) — 9KB
• bdsx-ex32_2.htm (EX-32.2) — 9KB
• 0001193125-25-262532.txt ( ) — 11441KB
• bdsx-20250930.xsd (EX-101.SCH) — 1839KB
• bdsx-20250930_htm.xml (XML) — 1992KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Balance Sheets as of September 30, 2025 and December 31, 2024 1 Condensed Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 2 Condensed Statements Stockholders' (Deficit) Equity for the Three and Nine Months Ended September 30, 2025 and 2024 3 Condensed Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 5 Notes to Condensed Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 34 Item 4.

Controls and Procedures

Controls and Procedures 35 PART II. OTHER INFORMATION 36 Item 1.

Legal Proceedings

Legal Proceedings 36 Item 1A.

Risk Factors

Risk Factors 36 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 39 Item 3. Defaults Upon Senior Securities 39 Item 4. Mine Safety Disclosures 39 Item 5. Other Information 39 Item 6. Exhibits 40 Signature 41 i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties, including but not limited to those set forth under the caption "Special Note Regarding Forward-Looking Statements" and Item 1A. "Risk Factors" of Part II of this Quarterly Report on Form 10-Q and those discussed in our other filings with the Securities and Exchange Commission (SEC), including the risks described in Item 1A. "Risk Factors" of Part I of our Annual Report on Form 10-K for the year ended December 31, 2024, which was filed on March 3, 2025. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potentially," "predict," "should," "will" or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, factors, and assumptions described under the section titled "Risk Factors" in this Report and in the section entit

—FINANCI AL INFORMATION

PART I—FINANCI AL INFORMATION

Financi al Statements (Unaudited)

Item 1. Financi al Statements (Unaudited). BIODESIX, INC. Condensed Balance S heets (in thousands, except share data) September 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents $ 16,604 $ 26,245 Accounts receivable, net of allowance for credit losses of $ 35 and $ 481 12,674 8,603 Other current assets 4,123 4,636 Total current assets 33,401 39,484 Noncurrent assets Property and equipment, net 25,462 27,828 Intangible assets, net 4,375 5,874 Operating lease right-of-use assets 2,942 1,767 Goodwill 15,031 15,031 Other long-term assets 7,511 7,260 Total noncurrent assets 55,321 57,760 Total assets $ 88,722 $ 97,244 Liabilities and Stockholders' (Deficit) Equity Current liabilities Accounts payable $ 3,617 $ 2,194 Accrued liabilities 9,720 10,064 Deferred revenue 2,773 678 Current portion of operating lease liabilities 1,394 719 Current portion of notes payable 11 21 Other current liabilities 637 641 Total current liabilities 18,152 14,317 Noncurrent liabilities Longterm notes payable, net of current portion 47,111 36,408 Long-term operating lease liabilities 24,412 24,828 Other long-term liabilities 769 815 Total noncurrent liabilities 72,292 62,051 Total liabilities 90,444 76,368 Commitments and contingencies Stockholders' equity Preferred stock, $ 0.001 par value, 5,000,000 authorized; 0 (2025 and 2024) issued and outstanding — — Common stock, $ 0.001 par value, 200,000,000 authorized; 7,954,541 (2025) and 7,274,578 (2024) shares issued and outstanding (a) 8 7 Additional paidin capital (a) 492,052 483,366 Accumulated deficit ( 493,782 ) ( 462,497 ) Total stockholders' (deficit) equity ( 1,722 ) 20,876 Total liabilities and stockholders' (deficit) equity $ 88,722 $ 97,244 (a) All share information, Common stock balances,

View Full Filing

View this 10-Q filing on SEC EDGAR